Cloud ERP to Support Commercial Readiness
February 20th 2023When a company reaches late-stages of clinical trials testing new drugs, systems need to be created to manage the manufacturing, sales, costs, internal controls, and more. A successful transition into commercializing a new drug depends on putting in place the right infrastructure and systems.
Leveraging Real-World Patient Journeys at Scale for Clinical Trial Strategies
January 25th 2023Readily available real-world data and advanced solutions are being used to stitch together the full patient journey, and these longitudinal insights are being used to identify and characterize trial populations and inform clinical trial design and execution strategies.
Understanding the true cost of transparency reporting
December 14th 2022When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.
A Changing Horizon for Digital Health Technologies
December 9th 2022Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.
Defining the 'Lab of the Future'
November 10th 2022There are three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs—the technologies, processes, ways of working, and data solutions.
Why eConsent Primes Studies & Patients for Success
September 12th 2022According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Quality control for human cell lines and other human samples manipulated ex vivo
August 25th 2022In this paper, learn about a variety of genetic analysis methods and how they’re valuable in ensuring that ex vivo human cells used for cell‑based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Download the white paper and read more about the importance of quality control (QC) for isolated human cells and tissues.
Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets
August 25th 2022For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs.
Seizing the Customer Experience Opportunity in Life Sciences
March 14th 2022To get a better understanding of how technology can power superior customer experiences, Salesforce commissioned research to explore what being customer-centric means for life sciences organizations and technology’s role in building stronger connections among people, data, and processes that ultimately lead to better health outcomes.
Smarter Signal Management: AI, big data, and predictive analytics
February 15th 2022What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.
The Next Domino: Automation, AI, and touchless safety case processing
February 15th 2022With the increasing volumes of adverse event reports and stagnant budgets, the time is now for a revolutionary change in drug and device safety case management. A robust management process is necessary for identifying and evaluating adverse events (AE) and reporting them properly to regulators.